Literature DB >> 23352659

Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA.

Patrick S C Leung1, Jinjun Wang, Phornnop Naiyanetr, Thomas P Kenny, Kit S Lam, Mark J Kurth, M Eric Gershwin.   

Abstract

Environmental stimulation is a major factor in the initiation and perpetuation of autoimmune diseases. We have addressed this issue and focused on primary biliary cirrhosis (PBC), an autoimmune disease of the liver. Immunologically, PBC is distinguished by immune mediated destruction of the intra hepatic bile ducts and the presence of high titer antimitochondrial autoantibodies (AMA) directed against a highly specific epitope within the lipoic acid binding domain of the pyruvate dehydrogenase E2 subunit (PDC-E2). We submit that the uniqueness of AMA epitope specificity and the conformational changes of the PDC-E2 lipoyl domain during physiological acyl transfer could be the lynchpin to the etiology of PBC and postulate that chemical xenobiotics modification of the lipoyl domain of PDC-E2 is sufficient to break self-tolerance, with subsequent production of AMA in patients with PBC. Indeed, using quantitative structure activity relationship (QSAR) analysis on a peptide-xenobiotic conjugate microarray platform, we have demonstrated that when the lipoyl domain of PDC-E2 was modified with specific synthetic small molecule lipoyl mimics, the ensuing structures displayed highly specific reactivity to PBC sera, at levels often higher than the native PDC-E2 molecule. Hereby, we discuss our recent QSAR analysis data on specific AMA reactivity against a focused panel of lipoic acid mimic in which the lipoyl di-sulfide bond are modified. Furthermore, data on the immunological characterization of antigen and Ig isotype specificities against one such lipoic acid mimic; 6,8-bis(acetylthio)octanoic acid (SAc), when compared with rPDC-E2, strongly support a xenobiotic etiology in PBC. This observation is of particular significance in that approximately one third of patients who have taken excessive acetaminophen (APAP) developed AMA with same specificity as patients with PBC, suggesting that the lipoic domain are a target of APAP electrophilic metabolites such as NAPQI. We submit that in genetically susceptible hosts, electrophilic modification of lipoic acid in PDC-E2 by acetaminophen or similar drugs can facilitate loss of tolerance and lead to the development of PBC.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352659      PMCID: PMC3622763          DOI: 10.1016/j.jaut.2012.12.007

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  80 in total

1.  Criteria for environmentally associated autoimmune diseases.

Authors:  Frederick W Miller; K Michael Pollard; Christine G Parks; Dori R Germolec; Patrick S C Leung; Carlo Selmi; Michael C Humble; Noel R Rose
Journal:  J Autoimmun       Date:  2012-07-06       Impact factor: 7.094

Review 2.  The molecular toxicology of acetaminophen.

Authors:  P David Josephy
Journal:  Drug Metab Rev       Date:  2005       Impact factor: 4.518

Review 3.  Lupus and Epstein-Barr.

Authors:  Judith A James; Julie M Robertson
Journal:  Curr Opin Rheumatol       Date:  2012-07       Impact factor: 5.006

4.  Epidemiology and natural history of primary biliary cirrhosis in a US community.

Authors:  W R Kim; K D Lindor; G R Locke; T M Therneau; H A Homburger; K P Batts; B P Yawn; J L Petz; L J Melton; E R Dickson
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

5.  The role of Acinetobacter in the pathogenesis of multiple sclerosis examined by using Popper sequences.

Authors:  Alan Ebringer; Taha Rashid; Clyde Wilson
Journal:  Med Hypotheses       Date:  2012-04-05       Impact factor: 1.538

6.  Primary biliary cirrhosis: further biochemical and immunological characterization of mitochondrial antigens.

Authors:  I Mendel-Hartvig; B D Nelson; L Lööf; T H Tötterman
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

7.  Solution structure and characterisation of the human pyruvate dehydrogenase complex core assembly.

Authors:  S Vijayakrishnan; S M Kelly; R J C Gilbert; P Callow; D Bhella; T Forsyth; J G Lindsay; O Byron
Journal:  J Mol Biol       Date:  2010-03-31       Impact factor: 5.469

8.  Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants.

Authors:  Gideon M Hirschfield; Xiangdong Liu; Chun Xu; Yue Lu; Gang Xie; Yan Lu; Xiangjun Gu; Erin J Walker; Kaiyan Jing; Brian D Juran; Andrew L Mason; Robert P Myers; Kevork M Peltekian; Cameron N Ghent; Catalina Coltescu; Elizabeth J Atkinson; E Jenny Heathcote; Konstantinos N Lazaridis; Christopher I Amos; Katherine A Siminovitch
Journal:  N Engl J Med       Date:  2009-05-20       Impact factor: 91.245

Review 9.  The causes of primary biliary cirrhosis: Convenient and inconvenient truths.

Authors:  M Eric Gershwin; Ian R Mackay
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

10.  The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase.

Authors:  J Van de Water; M E Gershwin; P Leung; A Ansari; R L Coppel
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  30 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Environmental Basis of Autoimmunity.

Authors:  Annarosa Floreani; Patrick S C Leung; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

Review 3.  Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

4.  The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis.

Authors:  Zongwen Shuai; Jinjun Wang; Madhu Badamagunta; Jinjung Choi; Guoxiang Yang; Weici Zhang; Thomas P Kenny; Kathryn Guggenheim; Mark J Kurth; Aftab A Ansari; John Voss; Ross L Coppel; Pietro Invernizzi; Patrick S C Leung; M Eric Gershwin
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

Review 5.  Xenobiotics and loss of tolerance in primary biliary cholangitis.

Authors:  Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 6.  The clinical significance of posttranslational modification of autoantigens.

Authors:  Maria G Zavala-Cerna; Erika A Martínez-García; Olivia Torres-Bugarín; Benjamín Rubio-Jurado; Carlos Riebeling; Arnulfo Nava
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 7.  A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.

Authors:  Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin
Journal:  Expert Rev Mol Diagn       Date:  2016-03-30       Impact factor: 5.225

Review 8.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 9.  Extrahepatic autoimmune conditions associated with primary biliary cirrhosis.

Authors:  Annarosa Floreani; Irene Franceschet; Nora Cazzagon; Alice Spinazzè; Alessandra Buja; Patrizia Furlan; Vincenzo Baldo; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 10.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.